PL2852668T3 - Oligonukleotydy do wprowadzania zmian w sekwencji docelowej cząsteczki RNA obecnej w żywej komórce - Google Patents
Oligonukleotydy do wprowadzania zmian w sekwencji docelowej cząsteczki RNA obecnej w żywej komórceInfo
- Publication number
- PL2852668T3 PL2852668T3 PL13760133.2T PL13760133T PL2852668T3 PL 2852668 T3 PL2852668 T3 PL 2852668T3 PL 13760133 T PL13760133 T PL 13760133T PL 2852668 T3 PL2852668 T3 PL 2852668T3
- Authority
- PL
- Poland
- Prior art keywords
- oligonucleotides
- sequence
- making
- change
- rna molecule
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261670681P | 2012-07-12 | 2012-07-12 | |
| US201261718801P | 2012-10-26 | 2012-10-26 | |
| EP13166465 | 2013-05-03 | ||
| EP13172515 | 2013-06-18 | ||
| EP13173818 | 2013-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2852668T3 true PL2852668T3 (pl) | 2016-11-30 |
Family
ID=49916369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13760133.2T PL2852668T3 (pl) | 2012-07-12 | 2013-07-12 | Oligonukleotydy do wprowadzania zmian w sekwencji docelowej cząsteczki RNA obecnej w żywej komórce |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9605255B2 (pl) |
| EP (2) | EP2852668B1 (pl) |
| JP (1) | JP6373833B2 (pl) |
| KR (1) | KR20150037968A (pl) |
| CN (1) | CN104640986B (pl) |
| AU (1) | AU2013287353B2 (pl) |
| BR (1) | BR112015000710A8 (pl) |
| CA (1) | CA2878934A1 (pl) |
| CY (1) | CY1117858T1 (pl) |
| DK (2) | DK2852668T3 (pl) |
| ES (2) | ES2698522T3 (pl) |
| HR (1) | HRP20160854T1 (pl) |
| HU (1) | HUE029977T2 (pl) |
| IL (1) | IL236654B (pl) |
| MX (1) | MX356625B (pl) |
| NZ (1) | NZ703824A (pl) |
| PL (1) | PL2852668T3 (pl) |
| PT (1) | PT2852668T (pl) |
| RS (1) | RS54944B1 (pl) |
| RU (1) | RU2663110C2 (pl) |
| SI (1) | SI2852668T1 (pl) |
| SM (1) | SMT201600234B (pl) |
| WO (1) | WO2014011053A1 (pl) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2635581C (en) | 2005-12-28 | 2017-02-28 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| CA2797118C (en) | 2010-04-22 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
| BR112015000710A8 (pt) | 2012-07-12 | 2018-04-03 | Proqr Therapeutics B V | Oligonucleotídeos para fazer uma alteração na sequência de um presente alvo de molécula de rna em uma célula viva |
| CA2944140C (en) | 2014-04-15 | 2022-10-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
| US10278991B2 (en) | 2014-05-14 | 2019-05-07 | Targimmune Therapeutics Ag | Polyethyleneimine polyethyleneglycol vectors |
| RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
| GB201418892D0 (en) * | 2014-10-23 | 2014-12-10 | Proqr Therapeutics B V | DNA editing |
| EP3230445B1 (en) * | 2014-12-12 | 2024-01-24 | Tod M. Woolf | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides |
| EP3712269A1 (en) * | 2014-12-17 | 2020-09-23 | ProQR Therapeutics II B.V. | Targeted rna editing |
| US20210401869A1 (en) * | 2015-02-20 | 2021-12-30 | Rosalind Franklin University Of Medicine And Science | Antisense Compounds Targeting Genes Associated with Cystic Fibrosis |
| GB201507926D0 (en) * | 2015-05-08 | 2015-06-24 | Proqr Therapeutics N V | Improved treatments using oligonucleotides |
| AU2016335032B2 (en) | 2015-10-05 | 2022-04-14 | Proqr Therapeutics Ii B.V. | Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion |
| CN108367021A (zh) * | 2015-10-15 | 2018-08-03 | 希望之城 | 包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 |
| JP6872560B2 (ja) * | 2016-05-06 | 2021-05-19 | エム． ウルフ、トッド | プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法 |
| US10988763B2 (en) | 2016-06-22 | 2021-04-27 | Proqr Therapeutics Ii B.V. | Single-stranded RNA-editing oligonucleotides |
| PL3507366T3 (pl) * | 2016-09-01 | 2021-05-04 | Proqr Therapeutics Ii B.V. | Chemicznie modyfikowane jednoniciowe oligonukleotydy edytujące rna |
| WO2018134301A1 (en) | 2017-01-19 | 2018-07-26 | Proqr Therapeutics Ii B.V. | Oligonucleotide complexes for use in rna editing |
| CN110612353A (zh) | 2017-03-03 | 2019-12-24 | 加利福尼亚大学董事会 | 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向 |
| CN107267516B (zh) * | 2017-07-28 | 2020-09-29 | 佛山科学技术学院 | 双sgRNA介导的基因精确修饰方法及应用 |
| US11261445B2 (en) | 2017-10-17 | 2022-03-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination treatment for cystic fibrosis |
| US11976092B2 (en) * | 2018-02-09 | 2024-05-07 | Ohio State Innovation Foundation | RNA nanostructures, methods of making, and uses thereof |
| JP7478923B2 (ja) | 2018-03-27 | 2024-05-08 | ユニバーシティ オブ ロチェスター | シュードウリジン化のための核酸分子 |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| WO2020154343A1 (en) * | 2019-01-22 | 2020-07-30 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| CN115038789A (zh) | 2019-12-02 | 2022-09-09 | 塑造治疗公司 | 治疗性编辑 |
| CN113397996A (zh) * | 2021-07-23 | 2021-09-17 | 河南省人民医院 | 一种抗菌漱口水及其制备方法 |
| CN114917227B (zh) * | 2022-05-19 | 2023-10-31 | 中国人民解放军海军军医大学 | 依伐卡托在制备抗蜱传脑炎病毒、西尼罗病毒、黄热病毒和基孔肯雅热病毒感染药中的应用 |
| US20250014676A1 (en) | 2023-03-15 | 2025-01-09 | Shape Therapeutics Inc. | Generative sequence screening with conditional gans, diffusion models, and denoising diffusion conditional gans |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616483A (en) * | 1992-06-11 | 1997-04-01 | Aktiebolaget Astra | Genomic DNA sequences encoding human BSSL/CEL |
| NZ266386A (en) | 1993-05-11 | 1997-11-24 | Univ North Carolina | Use of antisense rna oligonucleotides in regulating gene expression |
| US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| KR100556864B1 (ko) | 1997-05-13 | 2006-03-10 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 렌티바이러스-기원 유전자 전달 벡터 |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| US6683173B2 (en) | 1998-04-03 | 2004-01-27 | Epoch Biosciences, Inc. | Tm leveling methods |
| DE19909769A1 (de) | 1999-03-05 | 2000-09-07 | Bundesrepublik Deutschland Let | Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen |
| WO2005094370A2 (en) | 2004-03-29 | 2005-10-13 | The General Hospital Corporation | Oligonucleotide complex compositions and methods of use as gene alteration tools |
| EP2151248A1 (en) | 2008-07-30 | 2010-02-10 | Johann Bauer | Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses |
| EP2536738A4 (en) | 2010-02-08 | 2014-09-17 | Isis Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OR SUFFERING IN CONNECTION WITH REPEAT EXTENSIONS |
| AU2011244335B2 (en) * | 2010-04-23 | 2015-06-04 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat Beta-ENaC-related diseases |
| CN107353317A (zh) | 2010-05-28 | 2017-11-17 | 萨勒普塔医疗公司 | 具有修饰的亚基间键和/或端基的寡核苷酸类似物 |
| BR112015000710A8 (pt) * | 2012-07-12 | 2018-04-03 | Proqr Therapeutics B V | Oligonucleotídeos para fazer uma alteração na sequência de um presente alvo de molécula de rna em uma célula viva |
| EP2872632A1 (en) | 2012-07-12 | 2015-05-20 | ProQR Therapeutics B.V. | Exon replacement with stabilized artificial rnas |
-
2013
- 2013-07-12 BR BR112015000710A patent/BR112015000710A8/pt active Search and Examination
- 2013-07-12 SI SI201330214A patent/SI2852668T1/sl unknown
- 2013-07-12 EP EP13760133.2A patent/EP2852668B1/en active Active
- 2013-07-12 ES ES16166821T patent/ES2698522T3/es active Active
- 2013-07-12 PT PT137601332T patent/PT2852668T/pt unknown
- 2013-07-12 US US14/414,303 patent/US9605255B2/en not_active Expired - Fee Related
- 2013-07-12 NZ NZ703824A patent/NZ703824A/en not_active IP Right Cessation
- 2013-07-12 DK DK13760133.2T patent/DK2852668T3/en active
- 2013-07-12 PL PL13760133.2T patent/PL2852668T3/pl unknown
- 2013-07-12 CN CN201380047636.5A patent/CN104640986B/zh not_active Expired - Fee Related
- 2013-07-12 HU HUE13760133A patent/HUE029977T2/en unknown
- 2013-07-12 MX MX2015000506A patent/MX356625B/es active IP Right Grant
- 2013-07-12 AU AU2013287353A patent/AU2013287353B2/en not_active Ceased
- 2013-07-12 KR KR1020157002757A patent/KR20150037968A/ko not_active Ceased
- 2013-07-12 RS RS20160489A patent/RS54944B1/sr unknown
- 2013-07-12 RU RU2015104763A patent/RU2663110C2/ru not_active IP Right Cessation
- 2013-07-12 EP EP16166821.5A patent/EP3103872B1/en not_active Not-in-force
- 2013-07-12 CA CA2878934A patent/CA2878934A1/en not_active Abandoned
- 2013-07-12 JP JP2015521573A patent/JP6373833B2/ja not_active Expired - Fee Related
- 2013-07-12 HR HRP20160854TT patent/HRP20160854T1/hr unknown
- 2013-07-12 DK DK16166821.5T patent/DK3103872T3/en active
- 2013-07-12 ES ES13760133.2T patent/ES2584856T3/es active Active
- 2013-07-12 WO PCT/NL2013/050534 patent/WO2014011053A1/en not_active Ceased
-
2015
- 2015-01-11 IL IL236654A patent/IL236654B/en not_active IP Right Cessation
-
2016
- 2016-07-15 SM SM201600234T patent/SMT201600234B/it unknown
- 2016-07-22 CY CY20161100722T patent/CY1117858T1/el unknown
-
2017
- 2017-02-10 US US15/430,069 patent/US9994856B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL236654B (en) | Oligonucleotides to change the sequence of an RNA target molecule that is found in a living cell | |
| SG11201405542UA (en) | Artificial nucleic acid molecules | |
| DK2922554T3 (en) | Terminalt modificeret rna | |
| IL231983B (en) | Dna containing tricyclo-phosphorothioate | |
| IL235128A0 (en) | Preparation of a sample of nucleic acids | |
| AU2012304537A1 (en) | Closed nucleic acid structures | |
| GB2494239B (en) | Nucleic acid amplification | |
| SG10201607966UA (en) | Artificial nucleic acid molecules comprising a 5'top utr | |
| ZA201205891B (en) | Dna polymerases | |
| GB201204407D0 (en) | Nucleic acid molecule | |
| ZA201402646B (en) | Regulatory nucleic acid molecules for reliable gene expression in plants | |
| EP2608630A4 (en) | PLAN HEATING BODY | |
| GB201119903D0 (en) | Nucleic acid production and sequence analysis | |
| EP2798092A4 (en) | nucleic acid hybridization probes | |
| ZA201206793B (en) | Nucleic acid complexes | |
| LT2993232T (lt) | Nukleorūgščių gavimo būdas | |
| ZA201304998B (en) | Dna expression construct | |
| EP2844775A4 (en) | DNA SEQUENCING | |
| EP2594592A4 (en) | COMPLEX (NUCLEIC ACID) -POLYSACCHARIDE | |
| ZA201500184B (en) | Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell | |
| GB201107286D0 (en) | Nucleic acid preparation | |
| EP2791341A4 (en) | USE OF OLIGONUCLEOTIDES IN PLANT BIOLOGY | |
| GB201105387D0 (en) | Nucleic acid probes | |
| AU2011902654A0 (en) | Nucleic acid complex | |
| GB201100589D0 (en) | Central heating acid neutraliser |